Generic Name and Formulations:
Flunisolide 80mcg/inh; metered-dose inhaler with a built-in spacer.
Indications for AEROSPAN:
Maintenance treatment of asthma as prophylactic therapy. Limitation of use: not for relief of acute bronchospasm.
Do not use with an external spacer or holding chamber devices. ≥12yrs: initially 160mcg twice daily (approx. 12hrs apart); may increase to max 320mcg twice daily. Titrate to lowest effective dose after asthma stability achieved. Rinse mouth after use.
<6yrs: not recommended. Do not use with an external spacer or holding chamber devices. 6–11yrs: initally 80mcg twice daily (approx. 12hrs apart); may increase to max 160mcg twice daily. Titrate to lowest effective doe after asthma stability achieved. Rinse mouth after use.
Primary treatment of status asthmaticus or other acute asthma episodes where intensive measures are required.
Treat oropharyngeal candidiasis if develops. Immunosuppression. If exposed to chickenpox or measles, consider immune globulin prophylactic therapy; consider antiviral treatment if develops. Untreated tuberculosis or systemic infections. Ocular herpes simplex. Monitor for adrenal insufficiency when transferring from systemic steroids. May need supplemental systemic corticosteroids during periods of stress or a severe asthma attack. May unmask previously suppressed allergic conditions. Monitor for hypercorticism and HPA axis suppression (if occurs, discontinue gradually), growth in children, intraocular pressure, glaucoma, or cataracts. Assess bone mineral density (BMD) if risk factors exist (eg, prolonged immobilization, osteoporosis, postmenopausal, advanced age, others). Discontinue if paradoxical bronchospasm occurs; use alternative therapy. Pregnancy (Cat.C). Nursing mothers.
Pharyngitis, rhinitis, headache, sinusitis, increased cough; infections, adrenal suppression, decreased BMD.
Inhalation aerosol—5.1g (60 inh), 8.9g (120 inh)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|